Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) reports a corporate governance event dated June 23, 2026. The filing details the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Ron Philip to the Board of Directors, effective June 23, 2026. Key details include:
- Committee Assignments: Mr. Philip will serve on the Compensation Committee and the Science, Development and Commercial Advisory Committee.
- Term: His term lasts until the 2027 Annual Meeting of Stockholders or until a successor is elected.
- Compensation: Mr. Philip received a non-qualified stock option award to purchase 40,200 shares of common stock. The options vest in three equal installments over three years, subject to continued service. The exercise price is the closing stock price on June 23, 2026.
- Independence: The Board determined Mr. Philip satisfies Nasdaq independence requirements.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that Mr. Philip has no family relationships with other directors or officers and no undisclosed arrangements regarding his selection. His background includes serving as Executive Chair of CREATE Medicines (since Feb 2026) and previously as CEO of Orbital Therapeutics (acquired by Bristol-Myers Squibb in Dec 2025) and Spark Therapeutics.
Investor Verification Checklist
- Verify the closing stock price of AVTX on June 23, 2026, to determine the exercise price of the 40,200 options granted.
- Review the Company's Amended and Restated Non-Employee Director Compensation Plan for details on cash retainers or other fees not explicitly detailed in this 8-K.
- Confirm the composition of the Compensation Committee and Science, Development and Commercial Advisory Committee following this appointment.
- Check for any subsequent filings regarding the 2027 Annual Meeting of Stockholders to confirm the duration of Mr. Philip's term.